The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma
- 1 December 2015
- journal article
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 97-B (12) , 1698-1703
Abstract
The aim of this study was to evaluate the prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. A total of 80 patients with a primary parosteal osteosarcoma were included in this retrospective study. There were 51 females and 29 males with a mean age of 29.9 years (11 to 78). The mean follow-up was 11.2 years (1 to 40). Overall survival was 91.8% at five years and 87.8% at ten years. Local recurrence occurred in 14 (17.5%) patients and was associated with intralesional surgery and a large volume of tumour. On histological examination, 80% of the local recurrences were dedifferentiated high-grade tumours. A total of 12 (14.8%) patients developed pulmonary metastases, of whom half had either a dedifferentiated tumour or a local recurrence. Female gender and young age were good prognostic factors. Local recurrence was a poor prognostic factor for survival. Medullary involvement or the use of chemotherapy had no impact on survival. The main goal in treating a parosteal osteosarcoma must be to achieve a wide surgical margin, as inadequate margins are associated with local recurrence. Local recurrence has a significant negative effect on survival, as 80% of the local recurrences are high-grade dedifferentiated tumours, and half of these patients develop metastases. The role of chemotherapy in the treatment of parosteal osteosarcoma is not as obvious as it is in the treatment of conventional osteosarcoma. The mainstay of treatment is wide local excision. Cite this article: Bone Joint J 2015;97-B:1698–1703.Keywords
This publication has 27 references indexed in Scilit:
- Hemicortical resection and reconstruction using pasteurised autograft for parosteal osteosarcoma of the distal femurThe Bone & Joint Journal, 2013
- MDM2 and CDK4 Immunohistochemical Coexpression in High-grade OsteosarcomaAmerican Journal of Surgical Pathology, 2012
- Treatment and outcome of parosteal osteosarcoma: Biological versus endoprosthetic reconstructionJournal of Surgical Oncology, 2011
- Periosteal osteosarcomaCancer, 2010
- A Comparison of Intramedullary and Juxtacortical Low-grade Osteogenic SarcomaClinical Orthopaedics and Related Research, 2008
- Clinical outcome of parosteal osteosarcomaJournal of Surgical Oncology, 2007
- Periosteal osteosarcoma – a European review of outcomeEuropean Journal of Cancer, 2005
- Dedifferentiated parosteal osteosarcoma: The experience of the Rizzoli InstituteCancer, 2005
- Hemicortical allograft reconstruction after resection of low-grade malignant bone tumoursThe Journal of Bone and Joint Surgery. British volume, 2002
- Parosteal osteosarcoma: 2-23-year follow-up of 33 patientsActa Orthopaedica, 1991